Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.

ABSTRACT:

Opinion statement

When selecting therapy for patients with indolent non-Hodgkin lymphoma (iNHL) including follicular (FL), marginal zone (MZL), small lymphocytic (SLL), and lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM), there are several factors to consider. With a median age around 70 at diagnosis, many patients have accumulated comorbid conditions that may limit treatment options. Although incurable for most, iNHL is a chronic disease with a median overall survival measured in years to decades. This long natural history changes the risk-to-benefit balance with a lower acceptance of toxicity early in the treatment course compared to that of aggressive lymphomas. Despite a recent rapid increase in available therapies, overall progress in iNHL has been slow for

SUBMITTER: Leslie LA 

PROVIDER: S-EPMC8543415 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature